Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV004614915 | SCV005105344 | uncertain significance | Inborn genetic diseases | 2024-06-17 | criteria provided, single submitter | clinical testing | The c.4078A>C (p.K1360Q) alteration is located in exon 32 (coding exon 31) of the CEP290 gene. This alteration results from a A to C substitution at nucleotide position 4078, causing the lysine (K) at amino acid position 1360 to be replaced by a glutamine (Q). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Fulgent Genetics, |
RCV005003777 | SCV005630063 | uncertain significance | Leber congenital amaurosis 10; Meckel syndrome, type 4; Senior-Loken syndrome 6; Joubert syndrome 5; Bardet-Biedl syndrome 14 | 2024-01-09 | criteria provided, single submitter | clinical testing | |
Prevention |
RCV004733663 | SCV005345621 | uncertain significance | CEP290-related disorder | 2024-02-29 | no assertion criteria provided | clinical testing | The CEP290 c.4078A>C variant is predicted to result in the amino acid substitution p.Lys1360Gln. To our knowledge, this variant has not been reported in the literature or in a large population database, indicating this variant is rare. At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |